Preparation of reverse transcriptase envelope protein GALV env protein and its antibody
By synthesizing GALV-env protein genes, expression and purification, rabbit monoclonal antibodies were obtained, which solved the problem of lack of antibodies that recognize retroviral vectors in the prior art, achieved efficient detection of retrovirals, and promoted the progress of gene therapy. .
Patent Information
- Application Number
- CN202410912186.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-09
AI Technical Summary
The lack of antibodies in the prior art that can recognize the retroviral vector GALV env protein, resulting in the inability to effectively detect retrovirals, affecting the progress of gene therapy.
By synthesizing the GALV-env protein gene, building plasmids and expressing them, purifying the proteins, and animal immunization is performed to obtain rabbit monoclonal antibodies that recognize GALV env, and specific antibodies are obtained by screening and recombination using molecular cloning technology.
A highly specific and sensitive anti-GALV env rabbit monoclonal antibody was successfully prepared for detection of retroviruses, solving the recognition problem and promoting the development of gene therapy.
Smart Images

Figure CN118459577B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biopharmaceuticals, and in particular to the preparation of a reverse transcription envelope protein GALV env protein and an antibody thereof. Background Art
[0002] The retroviral vector currently used for CAR-T cell production is a replication-deficient virus constructed based on gag-pol (MuLV-gag-pol) of Moloney murine leukemia virus and cytoplasmic membrane protein (GALV env) of gibbon ape leukemia virus. GALV env is a membrane glycoprotein located on the surface of viral particles, which can mediate the attachment of viral particles to the surface of host cells and then fuse with receptors on the surface of host cell membranes, playing an important role in the process of viral infection of host cells. If the above retroviral vector lacks GALV env, it will not be able to obtain envelope proteins, and it will not be able to form viral particles to achieve gene transfer. Therefore, GALV env is of great significance in gene therapy.
[0003] Therefore, the above-mentioned retrovirus can be detected by identifying GALV env, but there is no antibody that can recognize GALV env. The present invention prepares GALV env antigen protein, immunizes animals, and harvests rabbit monoclonal antibodies that can recognize GALV env. The antibody can be used to develop a method for detecting retrovirus. Summary of the invention
[0004] The purpose of the present invention is to provide a method for preparing a reverse transcription envelope protein GALV env protein and an antibody thereof.
[0005] In order to solve the above technical problems, the present invention synthesizes the GALV-env protein gene and constructs a plasmid; electrophoreses the plasmid and expresses the GALV-env protein; purifies the expression product to obtain the GALV-env protein; immunizes animals with the GALV env protein as an antigen; enriches the peripheral blood mononuclear cells (PBMCs) of the immunized animals for specific B cells; then cultures and screens, and uses molecular cloning and recombination technology to obtain rabbit monoclonal antibodies against GALV env.
[0006] Preferably, the DNA sequence of the GALV env protein gene is as shown in SEQ ID NO.1.
[0007] Preferably, the amino acid sequence of the GALV env protein is as shown in SEQ ID NO. 2, and a 10×His tag is connected to the carboxyl terminus of the 1-489aa sequence on GALV-env to obtain the amino acid sequence of the GALV-env protein.
[0008] Preferably, the anti-GALV env rabbit monoclonal antibodies include C9, F8, and H6 antibodies.
[0009] Preferably, the anti-GALV env rabbit monoclonal antibody C9 has an amino acid sequence of the heavy chain variable region (VH) such as SEQ ID NO.5, and a DNA sequence of the C9 antibody VH such as SEQ ID NO.11. VH includes three antigenic determinants: VH C9 CDR1、VH C9 CDR2、VH C9 CDR3, whose amino acid sequences are SYWVS, FITFSATTYYATWAKG, VGDNIPDI.
[0010] Preferably, the anti-GALV env rabbit monoclonal antibody C9 has an amino acid sequence of the light chain variable region (VL) such as SEQ ID NO.6, and a DNA sequence of the C9 antibody VL such as SEQ ID NO.12. VL includes three antigenic determinants: VL C9 CDR1、VL C9 CDR2、VL C9 CDR3, whose amino acid sequences are QSSQSLYSSNHLS, DASTLAS, QGGYVCSTVDCWA.
[0011] Preferably, the anti-GALV env rabbit monoclonal antibody F8 has an amino acid sequence of the heavy chain variable region (VH) such as SEQ ID NO.7, and a DNA sequence of the F8 antibody VH such as SEQ ID NO.13. VH includes three antigenic determinants: VH F8 CDR1、VH F8 CDR2、VH F8 CDR3, whose amino acid sequences are NYAMD, INAGGSAVYASWAKG, GAYGDL.
[0012] Preferably, the anti-GALV env rabbit monoclonal antibody F8 has an amino acid sequence of the light chain variable region (VL) such as SEQ ID NO.8, and a DNA sequence of the F8 antibody VL such as SEQ ID NO.14. VL includes three antigenic determinants: VL F8 CDR1、VL F8 CDR2、VL F8 CDR3, whose amino acid sequences are QSIGNALA, AAANLAS, SAYWSSSSYGYT.
[0013] Preferably, the anti-GALV env rabbit monoclonal antibody H6 has an amino acid sequence of the heavy chain variable region (VH) such as SEQ ID NO.9, and a DNA sequence of the H6 antibody VH such as SEQ ID NO.15. VH includes three antigenic determinants: VH H6 CDR1、VH H6 CDR2、VH H6 CDR3, whose amino acid sequences are YYSMI, FIDSSANTWYASWVKG, and GDSDGWGGYYKGI.
[0014] Preferably, the anti-GALV env rabbit monoclonal antibody H6 has an amino acid sequence of the light chain variable region (VL) such as SEQ ID NO.10, and a DNA sequence of the H6 antibody VL such as SEQ ID NO.16. VL includes three antigenic determinants: VL H6 CDR1、VL H6 CDR2、VL H6 CDR3, whose amino acid sequences are QASHSVSSFLA, GASNLES, QHLAFGGGYQVA.
[0015] In one embodiment of the present invention, the specific steps of electroporating the plasmid and expressing the GALV-env protein include:
[0016] The CHO cells are revived, and after 3-5 passages, the cell precipitates are collected by centrifugation; a plasmid containing the GALV env gene and a transfection solution are added to the cell precipitates, and the mixture is mixed by pipetting; electroporation is performed to obtain electroporated cells; the electroporated cells are transferred into a shaking flask containing a DMEM culture medium, and statically cultured for 30-60 minutes; then the cells are transferred into a shaking incubator and cultured for 4-6 days; the supernatant is collected by centrifugation to obtain a crude extract of the GALV env protein.
[0017] Preferably, the transfection solution includes electroporation solution and N,N-dimethylmethanesulfonamide. During the electroporation process, N,N-dimethylmethanesulfonamide may facilitate the transfer of plasmids and stimulate the proliferation of CHO cells, thereby increasing the expression of GALV env protein antigen.
[0018] Preferably, the electroporation solution and N,N-dimethylmethanesulfonamide are mixed at a volume ratio of 1000:1-10 to obtain the transfection solution.
[0019] Preferably, the electroporation parameters are 1000-2000V and time 0.1-1S.
[0020] Preferably, the shaking culture conditions are 30-40°C, 100-120rpm, 5-8% CO2
[0021] More preferably, the DMEM medium also contains 10-6 -10 -5 mol / L of L-threbutanol. When L-threbutanol is used to culture CHO cells after electroporation, it may protect the CHO cells damaged after electroporation, allowing the CHO cells to grow and proliferate normally, and then produce more GALV env protein antigens.
[0022] The anti-GALV env rabbit monoclonal antibody prepared by the invention can be used for detecting retrovirus.
[0023] Compared with the prior art, the present invention has the following beneficial effects: in the process of preparing GALV env protein, N,N-dimethylmethanesulfonamide is added during electrotransformation to improve the expression of GALV env protein by CHO cells; when the electrotransformed CHO is cultured in a DMEM medium containing L-threbutanol, a protective effect is exerted on the CHO cells, thereby improving the expression of GALVenv protein by CHO cells. The present invention prepares rabbit monoclonal antibodies C9, F8, and H6 antibodies against GALV env, which have the advantages of good specificity and high sensitivity in recognizing GALV env protein. The above antibodies can be used to detect retroviruses and can be used to develop antibody-based methods for detecting retroviruses. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 The purity results of GALV env SDS-PAGE are shown in Figure 2.
[0025] Figure 2 Figures A, B and C are the SDS-PAGE results of antibodies C9, F8 and H6, respectively.
[0026] Figure 3 The curve fitting results of protein concentration and effect (OD value) of C9, F8 and H6 antibodies are shown. DETAILED DESCRIPTION
[0027] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0028] The experimental methods in the following examples, unless otherwise specified, are all conventional methods or conditions recommended by the manufacturer. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.
[0029] Example 1: Preparation of GALV env protein antigen
[0030] 1. Synthesis of GALV env protein gene
[0031] In the present invention, the carboxyl end of the 1-489aa sequence on GALV env is connected with 10×His tag to obtain the amino acid sequence of GALV env protein, such as SEQ ID NO. 2. The DNA sequence of GALV env protein is such as SEQ ID NO. 1, which is synthesized by Nanjing Qingke Technology Co., Ltd.
[0032] 2. Construction of plasmid containing GALV env gene
[0033] The GALV env protein gene was used as a template for PCR amplification to obtain the amplified product. The PCR enzyme was TaKaRa ExTaq® RRO01A; the primer sequences are shown in the table below.
[0034]
[0035] The amplified product and the CHO eukaryotic expression vector pSecTag2A-BN were digested with EcoR I / Not I and then connected to obtain a connection product; after enzyme digestion and identification, a connection product containing the GALV env gene, i.e., a plasmid containing the GALV env gene, was obtained; the plasmid containing the GALV env gene was transfected into competent cells and cultured to obtain a strain; then the plasmid was extracted with a rapid plasmid extraction kit, and the concentration and purity of the extracted plasmid containing the GALV env gene was determined with a NanoDrop instrument and diluted to 500 ng / ul. EcoR I and Not I were purchased from NEB. The rapid plasmid extraction kit was purchased from BioVo Medical Technology, catalog number BW-PD1502-02.
[0036] 3. Transfection of plasmid containing GALV env gene and expression of GALV env protein
[0037] 1) Take a 2×10 8 The number of CHO cells was revived in a 37°C water bath and inoculated into a 125 ml shake flask. The shake flask was placed in a shaker and cultured for 2 days. After the cell count, 2×10 8 Density subcultured into 125 ml shake flasks, and placed the shake flasks in a shaker for culture. After three subcultures, the CHO cells can be used for the next experiment. The cell culture conditions are 120 rpm, 8% CO2, and 37°C.
[0038] 2) Count the CHO cells after three passages and take 2.9×10 9The number of CHO cells was centrifuged to remove the supernatant to obtain a cell pellet, and the transfection solution was added to the cell pellet. After mixing by pipetting, a plasmid containing the GALV env gene was added to obtain a cell plasmid suspension; 10 ml of the cell plasmid suspension was added to an electroporation cup for electroporation. The specification of the electroporation cup is 10 ml. The electroporation parameters are voltage 1500 V, time 0.1 s. The transfection solution is 7 ml of electroporation solution. The electroporation solution was purchased from LONZA, item number V4LC-2002.
[0039] 3) After electroporation, the cells in the electroporation cup were divided into a shake flask containing 500 ml of DMEM culture medium and incubated statically for 40 min. Then, the shake flask was placed in a shaker for 24 h, and 25 ml of feed, 2 mmol / L sodium butyrate, and 5 ml of double antibody were added, which was recorded as D 0天 Cultivate and continue to cultivate for 4 days, i.e. D 4天 Culture. The cell culture conditions were 37°C, 120 rpm, 8% CO2. The feed was purchased from Oppman, catalog number P223635.
[0040] 4) CHO cells express GALV env protein and secrete it into the culture medium. 4天 The culture medium containing the CHO cells is centrifuged, and the supernatant, i.e., the crude extract of GALV env protein, is collected and then subjected to the next step of purification.
[0041] 4. Purification
[0042] The Ni affinity chromatography column was balanced with PBS, and then the crude extract of GALV env protein was added to the Ni affinity chromatography column, followed by washing with PBS and a 5mM imidazole solution at pH 8.0; then, a 150mM imidazole solution at pH 8.0 was added for elution to obtain a GALV env protein solution containing imidazole; then, the GALV env protein solution containing imidazole was transferred into a dialysis bag, and the dialysis bag was placed in a dialysis solution for dialysis, and after the dialysis, the GALV env protein antigen was obtained. The molecular weight cutoff of the dialysis bag was 50KDa; the dialysis solution was 20mM Tris-HCL+0.5M NaCl+6% trehalose, pH 8.0.
[0043] Example 2: Preparation of GALV env protein antigen
[0044] The difference between Example 2 and Example 1 is that the transfection solution of Example 2 is obtained by mixing 7 ml of electroporation solution and 35 ul of N,N-dimethylmethanesulfonamide.
[0045] Example 3: Preparation of GALV env protein antigen
[0046] The difference between Example 3 and Example 2 is that the transfection solution of Example 3 is obtained by mixing 7 ml of electroporation solution and 70 ul of N,N-dimethylmethanesulfonamide.
[0047] Example 4: Preparation of GALV env protein antigen
[0048] The difference between Example 4 and Example 3 is that in Example 4, the cells after electroporation are divided into DMEM culture medium containing L-threonol, and the concentration of L-threonol in the DMEM culture medium is 10 -6 mol / L.
[0049] Example 5: Preparation of GALV env protein antigen
[0050] The difference between Example 5 and Example 4 is that the concentration of L-thretobutanol in DMEM medium in Example 5 is 10 -5 mol / L.
[0051] Example 6: Preparation of GALV env protein antigen
[0052] The difference between Example 6 and Example 1 is that in Example 6, the cells after electroporation are divided into DMEM culture medium containing L-threonol, and the concentration of L-threonol in the DMEM culture medium is 10 -5 mol / L.
[0053] Example 7: Animal immunization and recombinant antibody harvesting
[0054] 1. Animal immunization
[0055] 1) The immunized animal in the present invention is a New Zealand rabbit. Two New Zealand rabbits are prepared. The immunized antigen is the GALV env protein antigen prepared in Example 1.
[0056] 2) Two New Zealand rabbits were immunized 4 times each, as shown in Table 1. During the immunization, each rabbit was injected with 200 µg of GALV env protein antigen. In the first immunization, the adjuvant used was Freund's complete adjuvant, in the second and third immunizations, the adjuvant used was Freund's incomplete adjuvant, and no adjuvant was added in the fourth immunization, i.e., the final immunization.
[0057] 3) Before the first immunization, 1 ml of blood from each of the two rabbits is needed in advance. After separating the plasma, the immune-free serum is obtained. One week after the final immunization, 1 ml of blood from each of the two rabbits is needed. After separating the plasma, the final immune serum is obtained. The above serum is added with 0.02% Proclin 300.
[0058] Table 1. Immunization schedule
[0059]
[0060] 2. Serum antibody titer detection
[0061] 1) The antibody titer of serum was tested by indirect ELISA. The final immunization serum was used as the test sample, and the non-immunization serum was used as the control sample.
[0062] 2) Adjust the protein concentration of antigen A and antigen B to 1µg / ml, add 100µl to each well of the ELISA plate, and coat overnight at 4℃. Antigen A is GALV env protein antigen. Antigen B is His-tag unrelated protein.
[0063] 3) On the second day, take out the ELISA plate, add 350µl / well of washing solution, soak the plate for 30 seconds, discard the liquid in the well, pat the plate dry to ensure that there is no washing solution left, and complete one wash. The washing solution is PBS with pH 7.4.
[0064] 4) Add 2% BSA for blocking, ensure that the sample is loaded within 15 minutes, incubate at room temperature for 2 hours, discard the liquid in the wells, add 350µl / well of washing solution, and wash the plate 5 times.
[0065] 5) Dilute the test samples and control samples from 1:2000 to 1:5120000 in a 4-fold gradient, and then add them to the corresponding wells of the ELISA plate in the order of Table 5, 100µl / well. Among them, add PBS to the Blank group, 100µl / well. After incubation at room temperature for 1 hour, discard the liquid in the wells, add 350µl / well of washing solution, and wash the plate 5 times.
[0066] 6) Dilute the secondary antibody at 1:40000 and add it to the ELISA plate, 100µl / well, incubate at room temperature for 20 minutes, discard the liquid in the well, add 350µl / well of washing solution, and wash the plate 5 times. The secondary antibody is Anti-Rabbit IgG Fc MonoclonalSecondary Antibody HRP conjugated, purchased from GenScript, catalog number A01856.
[0067] 7) Return the colorimetric solution to room temperature 10 minutes in advance, then add the colorimetric solution to the ELISA plate, 100µl / well, and incubate at room temperature in the dark for 15 minutes for color development. The colorimetric solution was purchased from Solarbio, with the catalog number PR1200.
[0068] 8) Then add 50µl / well stop solution to the ELISA plate. The color changes from blue to yellow. Gently shake the ELISA plate until the color is uniform. Read the light absorption value at 450nm within 10 minutes. The stop solution is 2M sulfuric acid.
[0069] 3. Serum antibody titer results
[0070] Positive well judgment criteria: the OD450 value of the test sample is greater than the OD450 reading of the control sample and the reading is greater than 0.5.
[0071] The results of serum antibody titer test are shown in Table 2. After four immunizations, the antibody titer of the serum in the rabbit reached 10 5 After the titer was confirmed, blood was taken from the New Zealand rabbits after final immunization for B cell collection and cloning.
[0072] Table 2. Serum antibody titer determination results
[0073]
[0074] Note: A is GALV env-his protein antigen, B is His-tag unrelated protein (negative control).
[0075] 4. B cell cloning
[0076] Experimental procedure: 15-30 ml of fresh blood was taken from the immunized rabbits to collect PBMCs, which were then enriched and cultured to obtain antigen-positive B cells. The antigen-positive B cells were then inoculated into a 96-well plate for a round of B cell cloning. The antibody titer of the culture supernatant of the antigen-positive B cells was then detected using the indirect ELISA method.
[0077] 1) Dilute antigens A and B with PBS, dilute them 4 times from 500 ng / ml to 0.488 ng / ml, then filter different concentrations of antigens A and B through a 0.22 μm filter membrane, add them to different 100 mm culture dishes and mark them, seal with sealing film, and coat overnight at 4°C. Antigen A is GALV env. Antigen B is a His-tag unrelated protein.
[0078] 2) On the second day, take out the above culture dish and wash it twice with PBS. Block the culture dish with blocking buffer at 37℃ for 2h to obtain the antigen-coated culture dish. The blocking buffer is 5% BSA.
[0079] 3) According to the amount of blood received, the tissue specimens were divided into 15 mL tubes, 5 mL / tube, and 5 mL of blood was added to the upper layer of Ficoll. The tube was centrifuged at 800g, 3 × 3 × 3 for 20 minutes. After centrifugation, the lymphocyte layer was transferred to a new 50 mL centrifuge tube, and an appropriate amount of PBS was added. The tube was centrifuged at 1500rpm, 9 × 7 × 7 for 5 minutes. The supernatant was discarded, and the cells were resuspended in red blood cell lysis buffer. The cells were incubated at room temperature in the dark for 15 minutes, and then an appropriate amount of PBS was added to stop the reaction. The tube was centrifuged at 1500rpm, 9 × 7 × 7 for 5 minutes, and the supernatant was discarded. An appropriate amount of CM culture medium was added to completely suspend the PBMCs, and the cells were counted twice. The obtained PBMCs were added to the above antigen-coated culture dish and placed in a 37°C incubator for enrichment culture.
[0080] 4) The enriched antigen-positive B cells were suspended in CM culture medium and mixed with feeder cells to obtain a cell suspension. The cell suspension was placed in a 96-well cell culture plate and cultured in a carbon dioxide incubator at 37°C and 5% CO2. The feeder cells were mouse thymic lymphoma cells (EL-4-B5).
[0081] 5. Antibody titer detection of culture supernatant
[0082] On the 6th day after the antigen-positive B cells were plated and cultured, the culture supernatant in the 96-well plate was taken for ELISA experiment. The determination method was as described in 2-serum antibody titer detection in this example, but the difference was that the culture supernatant was used as the sample to be tested.
[0083] If the OD450 value of the culture supernatant after dilution 512000 times is greater than 1.3, it means that the antibody titer of the B cells in the 96-well plate corresponding to the culture supernatant is good, and three antigen-positive B cells of C9, F8 and H6 were screened, and the results are shown in Table 3. Then, the total RNA of C9, F8 and H6 cells was extracted for antibody sequencing.
[0084] Table 3. Antibody titers of C9, F8, and H6 culture supernatants
[0085]
[0086] Note: A is GALV env-his protein, B is His-tag unrelated protein.
[0087] 6. Positive clone antibody sequencing
[0088] 1) According to the TRIzol® reagent technical manual, the total RNA of C9, F8, and H6 cells was extracted to obtain the total RNA of C9, F8, and H6 cells. The extraction of total RNA of C9, F8, and H6 cells was analyzed by agarose gel electrophoresis.
[0089] 2) After confirming that the extracted total RNA of C9, F8, and H6 cells is normal, reverse transcription-polymerase chain reaction is performed using Oligo dT Primer according to the technical manual of Prime Script TM 1stStrand cDNA Synthesis Kit to reverse transcribe the total RNA of C9, F8, and H6 cells into cDNA of C9, F8, and H6 cells, respectively. Then, according to the RACE (rapid-amplification of cDNA ends) standard operating procedure, the cDNA of C9, F8, and H6 cells is amplified to obtain the VH and VL DNA fragments of C9, F8, and H6 antibodies.
[0090] 3) Use standard molecular cloning procedures to clone the VH and VL DNA fragments of C9, F8, and H6 antibodies into the pMD™19-T Vector.
[0091] 4) Then transform and culture, and screen the clone strain with the correct size insert fragment by colony PCR, then extract the plasmid of the clone strain and send it to Nanjing Qingke Technology Co., Ltd. for sequencing.
[0092] 7. Recombinant antibody expression and purification
[0093] 1) The DNA fragments of C9 antibody VH and VL were connected by overlap extension polymerase chain reaction with a linker peptide (G4S)3 to construct the VH-(G4S)3-VL region sequence of C9 antibody. The VH-(G4S)3-VL region sequences of F8 antibody and H6 antibody were constructed by the same operation. Then, the VH-(G4S)3-VL region sequences of C9, F8 and H6 antibodies were cloned into the mammalian expression vector pCMV-2 for expression to obtain plasmids containing the VH-(G4S)3-VL region sequences of C9, F8 and H6 antibodies, respectively. Then, the above plasmids were respectively transfected into competent cells for amplification to obtain sufficient amounts of expression plasmids containing the VH-(G4S)3-VL region sequences of C9, F8 and H6 antibodies, respectively.
[0094] 2) HEK293 cells were first cultured in serum-free CD medium and then passaged three times before being used for the next experiment. Serum-free CD medium was purchased from Sino Biological, catalog number SMM 293-TI.
[0095] 3) The expression plasmid containing the VH-(G4S)3-VL region sequence of the C9 antibody was transfected into HEK293 cells. On the day of transfection, the HEK293 cells were adjusted to a cell density of 2×10 6 / ml, the culture system was 40ml. Then the expression plasmid containing the VH-(G4S)3-VL region sequence of the C9 antibody was mixed with the transfection reagent TF1 at a ratio of 1:10 (w / v) and added to 40ml HEK293 cells to start transfection, which was recorded as day 0. The transfection reagent used the reference reagent instructions. After the start of transfection, the feed solution was added on days 1, 3 and 5. The feed solution used the reference reagent instructions, thereby obtaining cells expressing the C9 antibody. According to the same operation steps, the expression plasmid containing the VH-(G4S)3-VL region sequence of the F8 and H6 antibodies was transfected, respectively, to obtain cells expressing the F8 antibody and the H6 antibody, respectively. The feed solution was purchased from Sino Biological, the catalog number is M293-SUPI-100. The transfection reagent TF1 was purchased from Sino Biological, the catalog number is STF02. The above cells were cultured in a shaker, and the culture conditions were 5% CO2, 150rpm.
[0096] 4) The cells expressing C9, F8 and H6 antibodies were cultured for 5 days respectively, and then the proteins were purified respectively. The protein purification steps are as follows:
[0097] The supernatant was harvested by centrifugation and filtered with a 0.22um filter to remove the remaining insoluble matter to obtain an antibody solution. After the chromatography column was balanced, the antibody solution was loaded for column purification. After washing and elution, the antibody protein was collected, and then the antibody protein was desalted to obtain the antibody.
[0098] The purified antibodies were C9 antibody, F8 antibody and H6 antibody.
[0099] Example 8: Biotin labeled antibody
[0100] The above three antibodies were biotinylated using the Thermo Scientific™ EZ-Link™ Sulfo-NHS-LC-Biotinylation Kit.
[0101] 1) According to the instructions, return all reagents and the above three antibodies to room temperature.
[0102] 2) According to the calculation method in the instruction manual, adjust the concentration of the above three antibodies to 2 mg / ml with PBS to prepare 0.5 ml of solution.
[0103] 3) Prepare 10 mM biotin reagent solution according to the instructions.
[0104] 4) Add appropriate amount of 10 mM biotin reagent solution to each of the three 2 mg / ml antibodies mentioned above.
[0105] 5) Incubate at room temperature for 30 minutes to complete the coupling of the antibody and biotin, and obtain biotin-coupled antibodies, namely C9-biotin antibody, F8-biotin antibody and H6-biotin antibody.
[0106] 6) After the coupling is completed, the concentration of biotin-coupled antibody is measured using a UV-visible spectrophotometer.
[0107] Experimental Example 1: Determination of the growth of CHO cells after electroporation
[0108] Add 200 µL of D in Example 1-6 to a 96-well plate. 0天 The cell suspension of cultured CHO cells was cultured at 37°C and 8% CO2 for 48 hours, and then the proliferation of the above CHO cells was detected by CCK-8 kit. The results are shown in Table 4.
[0109] Compared with Example 1 and Example 2 and 3, it can be seen that the OD of Example 2 and 3 450nm It is higher than that in Example 1, which indicates that the CHO cells in Examples 2 and 3 proliferate better, which may be because N,N-dimethylmethanesulfonamide has an effect on CHO cells. N,N-dimethylmethanesulfonamide may stimulate CHO cells during the electroporation of CHO cells and promote the growth of CHO cells in subsequent culture. Among them, when the volume ratio of electroporation solution to N,N-dimethylmethanesulfonamide in the transfection solution is 100:1, CHO cells proliferate better.
[0110] Further comparison of Examples 3, 4, and 5 shows that the OD 450nm The results are higher than those in Example 3. This may be because the use of DMEM medium containing L-threbutanol plays a role in culturing CHO cells. When L-threbutanol is used to culture CHO cells after electroporation, it may have a protective effect on CHO cells damaged after electroporation, and by reducing oxidative stress, etc., CHO cells can grow and proliferate normally. -5 mol / L L-threbutanol, CHO cells proliferated better.
[0111] In addition, when comparing Example 1 with Example 6, it can be seen that the OD 450nm The results are higher than those in Example 1, which also indicate that L-thretobutanol plays a role in the CHO cell culture process.
[0112] Table 4. CHO cell proliferation
[0113]
[0114] Test Example 2: Determination of the protein amount of GALV env protein antigen
[0115] The protein amount of the GALV env protein antigen in Examples 1-6 was detected by a BCA protein quantification kit, and the results are shown in Table 4. The BCA protein quantification kit was purchased from Bio-Technology, with a catalog number of C503021-0500.
[0116] Compared with Example 1 and Example 2 and 3, it can be seen that Example 2 and 3 have higher protein amounts of GALV env protein antigens, which may be because N,N-dimethylmethanesulfonamide plays a role during electrotransfection, thereby increasing the protein amount of GALV env protein antigens. N,N-dimethylmethanesulfonamide may increase the expression of GALV env protein antigens by promoting plasmid transfection and stimulating CHO cell growth. Among them, when the volume ratio of electrotransfection solution to N,N-dimethylmethanesulfonamide in the transfection solution is 100:1, the protein amount of GALV env protein antigen can be well increased.
[0117] Comparing Example 3 with Examples 4 and 5, it can be seen that Examples 4 and 5 have higher amounts of GALV env protein antigen. This may be because the use of DMEM medium containing L-threbutanol plays a role in culturing CHO cells. When L-threbutanol is used to culture CHO cells after electroporation, it may have a protective effect on CHO cells damaged after electroporation, by reducing oxidative stress, etc., so that CHO cells can grow and proliferate normally, and thus can produce more GALV env protein antigen. Among them, when the DMEM medium contains 10 -5 mol / L L-threbutanol, the protein amount of GALV env protein antigen can be better increased.
[0118] In addition, compared with Example 1 and Example 6, it can be seen that the protein amount of GALV env protein antigen in Example 6 is higher than that in Example 1, which also indicates that L-thretobutanol may play a role in the CHO cell culture process.
[0119] Table 5. Protein amount of GALV env protein antigen
[0120]
[0121] Test Example 3: Determination of the purity of GALV env protein antigen
[0122] The purity of the GALV env protein antigen obtained in Example 1 was tested by SDS-PAGE. The results are as follows: Figure 1 As shown in Figure 2, the SDS-PAGE results show that the purity of the GALV env protein antigen is good, with a purity higher than 95%.
[0123] Test Example 4: Determination of the purity and concentration of C9, F8 and H6 antibodies
[0124] The purity and concentration of the purified antibodies (C9 antibody, F8 antibody, and H6 antibody) were measured.
[0125] 1) Detect the purity of recombinant antibodies by SDS-PAGE.
[0126] The purity results of the three antibodies are as follows Figure 2 As shown in Figure 1, A is the result of SDS-PAGE of C9 antibody; B is the result of SDS-PAGE of F8 antibody; and C is the result of SDS-PAGE of H6 antibody.
[0127] The above results show that the purity of the three antibodies is good, higher than 95%.
[0128] 2) The protein concentrations of the three antibodies were measured using a BCA protein quantification kit, and the protein amount of the C9 antibody was 5.09 mg, the protein amount of the F8 antibody was 6.84 mg, and the protein amount of the H6 antibody was 3.24 mg.
[0129] Experimental Example 5: Determination of the affinity of biotin-conjugated antibodies
[0130] The ELISA experiment was performed as described in Example 7, 2—serum antibody titer detection, except that C9-biotin antibody, F8-biotin antibody and H6-biotin antibody were used as test samples, and then C9-biotin antibody, F8-biotin antibody and H6-biotin antibody were diluted 3 times from 2 µg / ml to 0.011 ng / ml.
[0131] Affinity test results Figure 3 GraphPad was used to analyze and plot the OD450 value and the corresponding antibody concentration, and the dose-effect curve was obtained by nonlinear regression curve fitting. In this way, the EC50 value corresponding to the antibody concentration when the effect on this curve reaches half of the maximum effect was calculated. The EC50 curve fitting of this experiment was analyzed using Graphpad8.0 software. The EC50 of C9-biotin antibody, F8-biotin antibody and H6-biotin antibody were 2.130ng / ml, 2.569ng / ml, and 3.181ng / ml, respectively.
[0132] Test Example 6: Amino Acid Sequences of C9, F8 and H6 Antibodies
[0133] The amino acid sequence of the VH of the C9 antibody is shown in SEQ ID NO. 5. The VH of the C9 antibody includes three antigenic determinants: VH C9 CDR1、VH C9 CDR2、VH C9 CDR3, whose amino acid sequences are: SYWVS, FITFSATTYYATWAKG, VGDNIPDI;
[0134] The amino acid sequence of the VL of the C9 antibody is shown in SEQ ID NO. 6. The VL of the C9 antibody includes three antigenic determinants: VL C9CDR1、VL C9 CDR2、VL C9 CDR3, the amino acid sequences are: QSSQSLYSSNHLS, DASTLAS, QGGYVCSTVDCWA.
[0135] The amino acid sequence of the VH of the F8 antibody is shown in SEQ ID NO. 7. The VH of the F8 antibody includes three antigenic determinants: VH F8 CDR1、VH F8 CDR2、VH F8 CDR3, whose amino acid sequences are: NYAMD, INAGGSAVYASWAKG, GAYGDL;
[0136] The amino acid sequence of the VL of the F8 antibody is shown in SEQ ID NO. 8. The VL of the F8 antibody includes three antigenic determinants: VL F8 CDR1、VL F8 CDR2、VL F8 CDR3, the amino acid sequences are: QSIGNALA, AAANLAS, SAYWSSSSYGYT.
[0137] The amino acid sequence of the VH of the H6 antibody is shown in SEQ ID NO. 9. The VH of the H6 antibody includes three antigenic determinants: VH H6 CDR1、VH H6 CDR2、VH H6 CDR3, whose amino acid sequences are: YYSMI, FIDSSANTWYASWVKG, GDSDGWGGYYKGI;
[0138] The amino acid sequence of the VL of the H6 antibody is shown in SEQ ID NO. 10. The VL of the H6 antibody includes three antigenic determinants: VL H6 CDR1、VL H6 CDR2、VL H6 CDR3, the amino acid sequences are: QASHSVSSFLA, GASNLES, QHLAFGGGYQVA.
[0139] Test Example 7: DNA sequences of C9, F8 and H6 antibodies
[0140] The DNA sequence of the C9 antibody VH is shown in SEQ ID NO. 11. The C9 antibody VH includes three antigenic determinants: VH C9 CDR1、VH C9 CDR2、VH C9CDR3, whose DNA sequences are: AGCTACTGGGTGAGC, TTCATTACTTTTAGTGCTACCACATACTACGCGACCTGGGCGAAAGGC, GTTGGTGATAATATTCCTGACATC;
[0141] The DNA sequence of the C9 antibody VL is shown in SEQ ID NO. 12. The C9 antibody VL includes three antigenic determinants: VL C9 CDR1、VL C9 CDR2、VL C9 CDR3, whose DNA sequences are: CAGTCCAGTCAGAGTCTTTATAGTAGCAACCACTTATCC, GATGCATCCACTCTGGCATCT, CAAGGCGGTTATGTTTGTAGTACTGTTGATTGTTGGGCT.
[0142] The DNA sequence of F8 antibody VH is shown in SEQ ID NO. 13. F8 antibody VH includes three antigenic determinants: VH F8 CDR1、VH F8 CDR2、VH F8 CDR3, whose DNA sequences are: AACTATGCAATGGAC, ATTAATGCTGGTGGTAGCGCAGTCTACGCGAGCTGGGCAAAAGGC, GGAGCATATGGTGATTTG;
[0143] The DNA sequence of F8 antibody VL is shown in SEQ ID NO. 14. F8 antibody VL includes three antigenic determinants: VL F8 CDR1、VL F8 CDR2、VL F8 CDR3, whose DNA sequences are: CAGGCCAGTCAGAGCATTGGCAATGCATTAGCC, GCTGCAGCCAATCTGGCATCT, AGTGCTTATTGGAGTAGTAGTAGTTATGGTTATACT.
[0144] The DNA sequence of the H6 antibody VH is shown in SEQ ID NO. 15. The H6 antibody VH includes three antigenic determinants: VH H6 CDR1、VH H6 CDR2、VH H6CDR3, whose DNA sequences are: TATTATTCAATGATC, TTCATTGATAGTAGTGCTAACACATGGTACGCGAGTTGGGTGAAAGGC, GGGGATAGTGATGGCTGGGGTGGATACTACAAAGGCATC;
[0145] The DNA sequence of the H6 antibody VL is shown in SEQ ID NO. 16. The H6 antibody VL includes three antigenic determinants: VL H6 CDR1、VL H6 CDR2、VL H6 CDR3, whose DNA sequences are: CAGGCCAGTCACAGCGTTAGTAGCTTCTTAGCC, GGTGCATCCAATCTGGAATCT, CAACATTTAGCCTTTGGTGGTGGTTATCAAGTTGCT.
[0146] This article uses specific examples to illustrate the principles and implementation methods of this application. The description of the above embodiments is only used to help understand the method and its core ideas of this application. The above is only the preferred implementation method of this application. It should be pointed out that due to the limitations of textual expression and the objective existence of infinite specific structures, ordinary technicians in this technical field can make several improvements, modifications or changes without departing from the principles of this application, and can also combine the above technical features in an appropriate manner; these improvements, modifications, changes or combinations, or the direct application of the concept and technical solution of the invention to other occasions without improvement, should be regarded as the scope of protection of this application.
Claims
1. A rabbit monoclonal antibody against GALV env, wherein the rabbit monoclonal antibody against GALV env comprises C9 antibody and / or F8 antibody and / or H6 antibody, wherein: The VH of the C9 antibody includes three antigenic determinants: VH C9 CDR1、VH C9 CDR2、VH C9 CDR3, whose amino acid sequences are SYWVS, FITFSATTYYATWAKG, VGDNIPDI; and, The VL of C9 antibody includes three antigenic determinants: VL C9 CDR1、VL C9 CDR2、VL C9 CDR3, whose amino acid sequences are QSSQSLYSSNHLS, DASTLAS, QGGYVCSTVDCWA; The VH amino acid sequence of the C9 antibody is shown in SEQ ID NO.5, and the VL amino acid sequence is shown in SEQ ID NO.6; The VH amino acid sequence of the F8 antibody is shown in SEQ ID NO.7, and the VL amino acid sequence is shown in SEQ ID NO.8; The VH amino acid sequence of the H6 antibody is shown in SEQ ID NO.9, and the VL amino acid sequence is shown in SEQ ID NO.
10.
2. The anti-GALV env rabbit monoclonal antibody according to claim 1, characterized in that The VH of the F8 antibody includes three antigenic determinants: VH F8 CDR1、VH F8 CDR2、VH F8 CDR3, whose amino acid sequences are NYAMD, INAGGSAVYASWAKG, GAYGDL; and, The VL of F8 antibody includes three antigenic determinants: VL F8 CDR1、VL F8 CDR2、VL F8 CDR3, whose amino acid sequences are QSIGNALA, AAANLAS, SAYWSSSSYGYT.
3. The anti-GALV env rabbit monoclonal antibody according to claim 1, characterized in that The amino acid sequence of VH of the F8 antibody is shown in SEQ ID NO.7, and the amino acid sequence of VL of the F8 antibody is shown in SEQ ID NO.
8.
4. The anti-GALV env rabbit monoclonal antibody according to claim 1, characterized in that The VH of the H6 antibody includes three antigenic determinants: VH H6 CDR1、VH H6 CDR2、VH H6 CDR3, whose amino acid sequences are YYSMI, FIDSSANTWYASWVKG, GDSDGWGGYYKGI; and, The VL of H6 antibody includes three antigenic determinants: VL H6 CDR1、VL H6 CDR2、VL H6 CDR3, whose amino acid sequences are QASHSVSSFLA, GASNLES, QHLAFGGGYQVA.
5. The anti-GALV env rabbit monoclonal antibody according to claim 1, characterized in that The amino acid sequence of VH of the H6 antibody is shown in SEQ ID NO.9, and the amino acid sequence of VL of the H6 antibody is shown in SEQ ID NO.
10.
6. Use of the anti-GALV env rabbit monoclonal antibody according to any one of claims 1 to 5 in the preparation of a reagent for detecting retroviruses, wherein the retrovirus is a replication-defective virus constructed by gibbon ape leukemia virus and / or GALV env protein.
Citation Information
Patent Citations
Ex vivo antibody production
CN106029873A
Methods for assessing the presence or absence of replication competent virus
CN109804089A
Anti-human immunodeficiency virus I type P24 antigen (HIV-1P24) rabbit monoclonal antibodies and application thereof
CN113683688A
Establishment and application of ELISA method for determining retrovirus envelope protein
CN118465260A
Monoclonal antibody of porcine endogenous retrovirus (PERV) capsid, hybridoma generating the antibody, and use thereof
TW200427837A
